Stay updated on Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial
Sign up to get notified when there's something new on the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page.

Latest updates to the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page
- Check4 days agoChange DetectedThe page footer now shows Revision: v3.6.4, replacing v3.6.3, indicating a small update to the ClinicalTrials.gov interface.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page's revision label changed from v3.6.2 to v3.6.3. This indicates a minor update to the page or its assets rather than a change to core content and user-facing features.SummaryDifference0.0%

- Check32 days agoChange DetectedThe page revision tag was updated from v3.6.0 to v3.6.2, indicating a minor build update. This update does not modify the study details or how users interact with the page.SummaryDifference0.0%

- Check46 days agoChange DetectedThe page adds new navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and shows recruitment is closed. It also standardizes the Intervention/Treatment heading and updates the site revision from v3.5.5 to v3.6.0.SummaryDifference0.5%

- Check54 days agoChange DetectedThe study record was updated to Terminated and now includes a new Strategic considerations section; the Petah Tikva location was broadened to include the Central District, and enrollment dates moved from estimated to actual, with a new revision timestamp.SummaryDifference0.7%

- Check75 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing the previous revision tag. This reflects a system-level update to the page without altering the study information.SummaryDifference0.0%

Stay in the know with updates to Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page.